EGFR and glioblastoma: In a previous study by our team, we have assessed, in vitro, the anti‐GBM potential of CD16158F‐ and CD16158V‐CRs against GBM cancer stem cells (CSC) in the presence or absence of therapeutic monoclonal antibodies (mAbs) against EGFR, which is expressed in almost 50% of GBM and GBM CSC.